222 related articles for article (PubMed ID: 37435731)
1. Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors.
Maltarollo VG; da Silva EB; Kronenberger T; Sena Andrade MM; de Lima Marques GV; Cândido Oliveira NJ; Santos LH; Oliveira Rezende Júnior C; Cassiano Martinho AC; Skinner D; Fajtová P; M Fernandes TH; Silveira Dos Santos ED; Rodrigues Gazolla PA; Martins de Souza AP; da Silva ML; Dos Santos FS; Lavorato SN; Oliveira Bretas AC; Carvalho DT; Franco LL; Luedtke S; Giardini MA; Poso A; Dias LC; Podust LM; Alves RJ; McKerrow J; Andrade SF; Teixeira RR; Siqueira-Neto JL; O'Donoghue A; de Oliveira RB; Ferreira RS
Future Med Chem; 2023 Jun; 15(11):959-985. PubMed ID: 37435731
[No Abstract] [Full Text] [Related]
2. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
3. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 M
Yang J; Lin X; Xing N; Zhang Z; Zhang H; Wu H; Xue W
J Chem Inf Model; 2021 Aug; 61(8):3917-3926. PubMed ID: 34279924
[TBL] [Abstract][Full Text] [Related]
5. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
6. The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.
Pang X; Xu W; Liu Y; Li H; Chen L
Eur J Med Chem; 2023 Sep; 257():115491. PubMed ID: 37244162
[TBL] [Abstract][Full Text] [Related]
7. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
Mandour YM; Zlotos DP; Alaraby Salem M
J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
[TBL] [Abstract][Full Text] [Related]
8. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
[TBL] [Abstract][Full Text] [Related]
9. Structure of M
Jin Z; Du X; Xu Y; Deng Y; Liu M; Zhao Y; Zhang B; Li X; Zhang L; Peng C; Duan Y; Yu J; Wang L; Yang K; Liu F; Jiang R; Yang X; You T; Liu X; Yang X; Bai F; Liu H; Liu X; Guddat LW; Xu W; Xiao G; Qin C; Shi Z; Jiang H; Rao Z; Yang H
Nature; 2020 Jun; 582(7811):289-293. PubMed ID: 32272481
[TBL] [Abstract][Full Text] [Related]
10. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 3-oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin derivatives as SARS-CoV-2 main protease inhibitors through virtual screening and biological evaluation.
Dou X; Sun Q; Liu Y; Lu Y; Zhang C; Xu G; Xu Y; Huo T; Zhao X; Su L; Xing Y; Lai L; Jiao N
Bioorg Med Chem Lett; 2024 Jan; 97():129547. PubMed ID: 37944867
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Gao S; Song L; Claff T; Woodson M; Sylvester K; Jing L; Weiße RH; Cheng Y; Sträter N; Schäkel L; Gütschow M; Ye B; Yang M; Zhang T; Kang D; Toth K; Tavis J; Tollefson AE; Müller CE; Zhan P; Liu X
J Med Chem; 2022 Dec; 65(24):16902-16917. PubMed ID: 36475694
[TBL] [Abstract][Full Text] [Related]
13. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
[TBL] [Abstract][Full Text] [Related]
14. Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity.
Liu C; Puopolo T; Li H; Cai A; Seeram NP; Ma H
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144858
[TBL] [Abstract][Full Text] [Related]
15. Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (M
Elgohary AM; Elfiky AA; Pereira F; Abd El-Aziz TM; Sobeh M; Arafa RK; El-Demerdash A
Comput Biol Med; 2022 Aug; 147():105738. PubMed ID: 35777088
[TBL] [Abstract][Full Text] [Related]
16. Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m
Badavath VN; Kumar A; Samanta PK; Maji S; Das A; Blum G; Jha A; Sen A
J Biomol Struct Dyn; 2022 Apr; 40(7):3110-3128. PubMed ID: 33200681
[TBL] [Abstract][Full Text] [Related]
17. Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors.
Fink EA; Bardine C; Gahbauer S; Singh I; Detomasi TC; White K; Gu S; Wan X; Chen J; Ary B; Glenn I; O'Connell J; O'Donnell H; Fajtová P; Lyu J; Vigneron S; Young NJ; Kondratov IS; Alisoltani A; Simons LM; Lorenzo-Redondo R; Ozer EA; Hultquist JF; O'Donoghue AJ; Moroz YS; Taunton J; Renslo AR; Irwin JJ; García-Sastre A; Shoichet BK; Craik CS
Protein Sci; 2023 Aug; 32(8):e4712. PubMed ID: 37354015
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M
Santos LH; Kronenberger T; Almeida RG; Silva EB; Rocha REO; Oliveira JC; Barreto LV; Skinner D; Fajtová P; Giardini MA; Woodworth B; Bardine C; Lourenço AL; Craik CS; Poso A; Podust LM; McKerrow JH; Siqueira-Neto JL; O'Donoghue AJ; da Silva Júnior EN; Ferreira RS
J Chem Inf Model; 2022 Dec; 62(24):6553-6573. PubMed ID: 35960688
[TBL] [Abstract][Full Text] [Related]
19. Discovery of the covalent SARS-CoV-2 M
Zhang YN; Zhu GH; Liu W; Chen XX; Xie YY; Xu JR; Jiang MF; Zhuang XY; Zhang WD; Chen HZ; Ge GB
J Med Virol; 2023 Nov; 95(11):e29208. PubMed ID: 37947293
[TBL] [Abstract][Full Text] [Related]
20. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA
Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
